期刊
PARASITE IMMUNOLOGY
卷 38, 期 3, 页码 182-192出版社
WILEY
DOI: 10.1111/pim.12292
关键词
alveolar echinococcosis; Echinococcus multilocularis; FGL2; immunotolerance; TGF-beta; Tregs
资金
- Swiss National Science Foundation [31003A_141039/1, 31003A_160108/1]
- Natural Science Fundation of China [81260452]
- Swiss National Science Foundation (SNF) [31003A_160108] Funding Source: Swiss National Science Foundation (SNF)
Alveolar echinococcosis (AE) is a clinically very severe zoonotic helminthic disease, characterized by a chronic progressive hepatic damage caused by the continuous proliferation of the larval stage (metacestode) of Echinococcus multilocularis. The proliferative potential of the parasite metacestode tissue is dependent on the nature/function of the periparasitic immune-mediated processes of the host. Immune tolerance and/or down-regulation of immunity are a marked characteristic increasingly observed when disease develops towards its chronic (late) stage of infection. In this context, explorative studies have clearly shown that T regulatory (Treg) cells play an important role in modulating and orchestrating inflammatory/immune reactions in AE, yielding a largely Th2-biased response, and finally allowing thus long-term parasite survival, proliferation and maturation. AE is fatal if not treated appropriately, but the current benzimidazole chemotherapy is far from optimal, and novel options for control are needed. Future research should focus on the elucidation of the crucial immunological events that lead to anergy in AE, and focus on providing a scientific basis for the development of novel and more effective immunotherapeutical options to support cure AE by abrogating anergy, anticipating also that a combination of immuno- and chemotherapy could provide a synergistic therapeutical effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据